acyl-CoA dehydrogenase short chainGenealiases: ACAD3 · SCAD
Q-omics provides the consensus-scored ACADS profile across patient tissues and cancer cell-line models. ACADS expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ACADS is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, ACADS RNA expression shows 18,803 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, COAD, and TGCT as cancer lineages where ACADS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACADS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACADS survival associations across molecular data types. ACADS RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACADS RNA expression–survival associations across cancer types. High ACADS expression shows unfavorable associations in LGG, but favorable associations in KIRC, UCEC, KIRP, SCLC and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify KIRC as the clearest survival context for ACADS RNA expression.
This table summarizes ACADS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ACADS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACADS shows lower tumor expression in COAD, THCA, LIHC, LUAD, LUSC and HNSC. The COAD box plot shows higher ACADS RNA expression in normal versus tumor tissue (log2 FC = −2.555, t-test p < 0.001).
This table shows molecular features associated with ACADS in patient tissues and cancer cell lines. In patient samples, ACADS shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ACADS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and UPPER_AERODIGESTIVE_TRACT.
